TY - JOUR
T1 - Protective effect of dl-α-lipoic acid on cyclophosphamide induced hyperlipidemic cardiomyopathy
AU - Mythili, Yenjerla
AU - Sudharsan, Periyasamy Thandavan
AU - Sudhahar, Varatharajan
AU - Varalakshmi, Palaninathan
N1 - Funding Information:
The authors, Y. Mythili and P.T. Sudharsan gratefully acknowledge the financial assistance awarded by the Indian Council of Medical Research (ICMR), New Delhi, India in the form of Senior Research Fellowship.
PY - 2006/8/14
Y1 - 2006/8/14
N2 - Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.
AB - Cyclophosphamide is a potent alkylating agent used in cancer chemotherapy and immunosuppression. The present study is aimed at evaluating the role of a potent antioxidant lipoic acid in cyclophosphamide induced hyperlipidemic cardiomyopathy. Adult male Wistar rats were divided into four treatment groups. Two groups received single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce cardiotoxicity, one of these groups received lipoic acid treatment (25 mg/kg body weight, orally for 10 days). A vehicle treated control group and a lipoic acid drug control were also included. Cyclophosphamide administration resulted in abnormal elevation of serum lipids. Similarly in the cardiac tissue, the levels of free cholesterol, esterified cholesterol, triglycerides were increased significantly (P < 0.05) while the levels of phospholipids and free fatty acids were reduced significantly unlike serum (P < 0.05). Serum Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL) cholesterol increased significantly (P < 0.05) while High Density Lipoprotein (HDL) cholesterol (P < 0.05) decreased significantly when compared to controls. These changes corroborated with the abnormal distortion in the activities of lipid metabolizing enzymes in cyclophosphamide treated group. Supplementation of lipoic acid reverted these abnormalities in the lipid levels and activities of lipid metabolizing enzymes to near normalcy after cyclophosphamide administration.
KW - Cyclophosphamide
KW - Heart
KW - Hyperlipidemia
KW - Lipoic acid
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=33746210028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746210028&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2006.06.007
DO - 10.1016/j.ejphar.2006.06.007
M3 - Article
C2 - 16814280
AN - SCOPUS:33746210028
SN - 0014-2999
VL - 543
SP - 92
EP - 96
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -